Relationship between the Renal Function and Adverse Clinical Events in Patients with Atrial Fibrillation: A Japanese Multicenter Registry Substudy

Journal of Clinical Medicine

卷:9

Hironori Haruta¹  Naoya Matsumoto²  Katsuaki Yokoyama²  Yasuhumi Yuzawa²  Atsushi Hirayama³  Yasuo Okumura³  Kimie Okubo⁴  Satoru Itou⁵  Ken Arima⁶  Rikitake Kogawa⁶  Keiichiro Kuronuma⁷  Eizo Tachibana⁷  Masaaki Chiku⁸  Kunio Kondo⁹  Tomobumi Kotani¹⁰  on behalf of the SAKURA AF Registry Investigators¹¹  Yasumi Ohno¹²  Motoyuki Onikura¹³  Toshiaki Kojima¹⁴  Kazumiki Nomoto¹⁵  Kazumasa Sonoda¹⁵  Seiji Fukushima¹⁶  Fumiyuki Takahashi¹⁷  Michiaki Matsumoto¹⁸  Koji Oiwa¹⁸ 

[1] Asaka Medical Center, Asaka 351-0023, Japan;

[2] Department of Cardiology, Nihon University Hospital, Tokyo 101-8309, Japan;

[3] Division of Cardiology, Nihon University Itabashi Hospital, Tokyo 173-8610, Japan;

[4] Itabashi Medical Association Hospital, Tokyo 175-0082, Japan;

[5] Itou Cardiovascular Clinic, Tokorozawa 359-1124, Japan;

[6] Kasukabe Municipal Hospital, Kasukabe 344-8588, Japan;

[7] Kawaguchi Municipal Medical Center, Kawaguchi 333-0833, Japan;

[8] Keiai Clinic, Tokyo 173-0036, Japan;

[9] Kondo Clinic, Tokyo 167-0022, Japan;

[10] Makita General Hospital, Tokyo 143-0016, Japan;

[11] Membership of the SAKURA AF Registry Investigators is provided in the Acknowledgments.;

[12] Ohno Medical Clinic, Tokyo 173-0004, Japan;

[13] Onikura Clinic, Yachiyo 276-0023, Japan;

[14] Sekishindo Hospital, Kawagoe 350-1123, Japan;

[15] Tokyo Rinkai Hospital, Tokyo 134-0086, Japan;

[16] Ukima Central Hospital, Tokyo 115-0052, Japan;

[17] Yasuda Hospital, Tokyo 175-0094, Japan;

[18] Yokohama Chuo Hospital, Yokohama 231-0023, Japan;

关键词: adverse clinical events;    atrial fibrillation;    direct oral anticoagulant;    japanese;    renal function;   

DOI  :  10.3390/jcm9010167

来源: DOAJ

【 摘 要 】

Background: Atrial fibrillation (AF) and chronic kidney disease (CKD) often coexist, but the real-world data after approval of direct oral anticoagulants (DOACs) are still lacking in Japan. We investigated the association of the baseline renal function and adverse clinical events and risk of adverse clinical events with DOACs compared to warfarin for each renal functional level in Japanese AF patients. Methods: The present substudy was based on the SAKURA AF Registry, a Japanese multicenter observational registry (median follow-up period: 39 months). The creatinine clearance (CrCl) values were estimated by the Cockcroft–Gault formula, and divided into normal renal function, and mild and moderate-severe CKD (CrCl ≥ 80, 50–79, <50 mL/min). Results: In the SAKURA AF Registry, the baseline CrCl data were available for 3242 patients (52% for DOAC and 48% for warfarin user). The relative risk of adverse clinical events was significantly higher in the patients with a CrCl < 50 mL/min as compared to those with a CrCl ≥ 80 mL/min (adjusted HRs: 2.53 for death, 2.53 for cardiovascular [CV] events, 2.13 for strokes, and 1.83 for major bleeding). Risks of all adverse clinical events were statistically even between DOAC and warfarin users for each renal function level. Conclusion: Moderate–severe CKD was associated with a higher mortality, CV events, strokes, and major bleeding than normal renal function. The safety and effectiveness of DOACs over warfarin were similar for each renal function level. By a worsening renal function, the incidence of adverse clinical events increased, especially deaths and CV events as compared to strokes and major bleeding.

【 授权许可】

Unknown